A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
Year of publication: |
2019
|
---|---|
Authors: | Nguyen Cuc Thi Thu ; Petrelli, Fabio ; Scuri, Stefania ; Nguyen Thanh Binh ; Grappasonni, Iolanda |
Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 20.2019, 5, p. 763-777
|
Subject: | Cost-effectiveness | Overview | QHES | Report's quality | Gesundheitsökonomik | Health economics | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Gesundheitskosten | Health care costs | Arzneimittel | Pharmaceuticals | USA | United States | Krebskrankheit | Cancer | Theorie | Theory |
-
Barbier, Michaela Carla, (2021)
-
Are biopharmaceutical budget caps good public policy?
Goldman, Dana P., (2016)
-
Jin, Huajie, (2019)
- More ...
-
Spatial impact of foreign direct investment on poverty reduction in Vietnam
Do Quynh Anh, (2021)
-
Factors affecting risk attitude of rice farmers: Evidence from Vietnam's Mekong Delta
Dong, Khuu Thi Phuong, (2022)
-
The impact of economic uncertainty on housing, labor and financial markets
Binh Nguyen Thanh, (2017)
- More ...